In practice, he adds, those patients who dont respond often have more advanced obesity, with a body mass index (BMI) above 40a group that has been underrepresented in many GLP1 studies, where the average BMI has typically been in the mid30s
Preclinical research in animal models provides robust evidence for BPC-157s capacity to accelerate healing of damaged tendons, ligaments, muscle, and bone, while also protecting against gastrointestinal and neural injury
Clinical trials show that individuals who have been treated can expect an average of 24 percent of their total body weight loss within about 48 weeks
Inhibition of the BTK-IDO-mTOR axis promotes differentiation of monocyte-lineage dendritic cells and enhances anti-tumor T cell immunity
Initially designed to regulate blood sugar by mimicking the GLP-1 hormone, its appetite-suppressing properties have made it a beacon of hope for weight loss
Administration: Subcutaneous or intramuscular injection 5-10mg daily for 10-20 days, repeated 2-4 times yearly in cycles